Oral Mucositis-Related Oropharyngeal Pain and Correlative Tumor Necrosis Factor-α Expression in Adult Oncology Patients Undergoing Hematopoietic Stem Cell Transplantation
Background: Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-α (TNF-α) is a key pathogenic component of oral mucositis. Objectives: The prima...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics Jg. 29; H. 11; S. 2547 - 2561 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
EM Inc USA
2007
|
| Schlagworte: | |
| ISSN: | 0149-2918, 1879-114X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background: Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-α (TNF-α) is a key pathogenic component of oral mucositis.
Objectives: The primary purpose of this study was to describe oral mucositis-related oropharyngeal pain in the setting of HSCT. A secondary purpose was to assess the effectiveness of molecular biology methods for measuring TNF-α concentrations in plasma, saliva, and buccal epithelial cells in patients with oral mucositis undergoing HSCT.
Methods: This descriptive, correlative study recruited subjects aged ≥ 18 years who were scheduled to receive HSCT with CT. Subjects assessed their pain at baseline and 9 days (±24 hours) after CT using a pain visual analog scale (VAS) from 0 = no pain to 10 = worst possible pain, as well as word descriptors of sensory and affective pain. The extent and severity of oral mucositis were evaluated using the Oral Mucositis Assessment Scale. Saliva and blood samples and buccal brush biopsies were obtained at the same time points. Salivary and plasma TNF-**α concentrations were measured using an enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction testing was used to measure buccal TNF-α gene expression. To determine the optimal method of RNA isolation, samples were extracted using 3 different methods: TRIzol, RNeasy, and RLT/TRIzol.
Results: Twenty-five adult men and women (mean age, 46 years; age range, 32-68 years; 64% white) underwent HSCT with CT. Significant differences from baseline to day 9 were observed in the severity of oral mucositis (
P < 0.001), the overall intensity of oral pain (
P < 0.05), the overall intensity of oral pain with swallowing (
P < 0.01), the sensory dimension of oral pain with swallowing (
P < 0.05), and the sensory and affective dimension of oral pain with swallowing (
P < 0.05). The severity of oral mucositis was significantly associated with the overall intensity of oral pain (
P < 0.05). Although mean scores for oral pain were low, 8 subjects had clinically unacceptable pain VAS scores (>3) while receiving opioids. Fourteen subjects had measurable increases in buccal TNF-α RNA expression at day 9 (
P = 0.027 vs baseline), as measured using the TRIzol method, which was found to be the best method for measuring this variable. TNF-α RNA content in buccal samples was significantly associated with the worst intensity of oral pain with swallowing (partial R
2 = 0.19;
P < 0.05).
Conclusions: Despite the use of opioids, oropharyngeal pain remained a treatment challenge in approximately one third of these subjects after CT with HSCT. The sensitive assay used to measure TNF-α gene expression in buccal cells may be useful in investigating molecular events in oral mucositis-related pain, as well as in evaluating the therapeutic response to investigational agents. |
|---|---|
| AbstractList | Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-alpha (TNF-alpha) is a key pathogenic component of oral mucositis.
The primary purpose of this study was to describe oral mucositis-related oropharyngeal pain in the setting of HSCT. A secondary purpose was to assess the effectiveness of molecular biology methods for measuring TNF-alpha concentrations in plasma, saliva, and buccal epithelial cells in patients with oral mucositis undergoing HSCT.
This descriptive, correlative study recruited subjects aged >or= 18 years who were scheduled to receive HSCT with CT. Subjects assessed their pain at baseline and 9 days (+/-24 hours) after CT using a pain visual analog scale (VAS) from 0=no pain to 10=worst possible pain, as well as word descriptors of sensory and affective pain. The extent and severity of oral mucositis were evaluated using the Oral Mucositis Assessment Scale. Saliva and blood samples and buccal brush biopsies were obtained at the same time points. Salivary and plasma TNF-alpha concentrations were measured using an enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction testing was used to measure buccal TNF-alpha gene expression. To determine the optimal method of RNA isolation, samples were extracted using 3 different methods: TRIzol, RNeasy, and RLT/TRIzol.
Twenty-five adult men and women (mean age, 46 years; age range, 32-68 years; 64% white) underwent HSCT with CT. Significant differences from baseline to day 9 were observed in the severity of oral mucositis (P<0.001), the overall intensity of oral pain (P<0.05), the overall intensity of oral pain with swallowing (P<0.01), the sensory dimension of oral pain with swallowing (P<0.05), and the sensory and affective dimension of oral pain with swallowing (P<0.05). The severity of oral mucositis was significantly associated with the overall intensity of oral pain (P<0.05). Although mean scores for oral pain were low, 8 subjects had clinically unacceptable pain VAS scores (>3) while receiving opioids. Fourteen subjects had measurable increases in buccal TNF-alpha RNA expression at day 9 (P=0.027 vs baseline), as measured using the TRIzol method, which was found to be the best method for measuring this variable. TNF-alpha RNA content in buccal samples was significantly associated with the worst intensity of oral pain with swallowing (partial R(2)=0.19; P<0.05).
Despite the use of opioids, oropharyngeal pain remained a treatment challenge in approximately one third of these subjects after CT with HSCT. The sensitive assay used to measure TNF-alpha gene expression in buccal cells may be useful in investigating molecular events in oral mucositis-related pain, as well as in evaluating the therapeutic response to investigational agents. Background: Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-α (TNF-α) is a key pathogenic component of oral mucositis. Objectives: The primary purpose of this study was to describe oral mucositis-related oropharyngeal pain in the setting of HSCT. A secondary purpose was to assess the effectiveness of molecular biology methods for measuring TNF-α concentrations in plasma, saliva, and buccal epithelial cells in patients with oral mucositis undergoing HSCT. Methods: This descriptive, correlative study recruited subjects aged ≥ 18 years who were scheduled to receive HSCT with CT. Subjects assessed their pain at baseline and 9 days (±24 hours) after CT using a pain visual analog scale (VAS) from 0 = no pain to 10 = worst possible pain, as well as word descriptors of sensory and affective pain. The extent and severity of oral mucositis were evaluated using the Oral Mucositis Assessment Scale. Saliva and blood samples and buccal brush biopsies were obtained at the same time points. Salivary and plasma TNF-**α concentrations were measured using an enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction testing was used to measure buccal TNF-α gene expression. To determine the optimal method of RNA isolation, samples were extracted using 3 different methods: TRIzol, RNeasy, and RLT/TRIzol. Results: Twenty-five adult men and women (mean age, 46 years; age range, 32-68 years; 64% white) underwent HSCT with CT. Significant differences from baseline to day 9 were observed in the severity of oral mucositis ( P < 0.001), the overall intensity of oral pain ( P < 0.05), the overall intensity of oral pain with swallowing ( P < 0.01), the sensory dimension of oral pain with swallowing ( P < 0.05), and the sensory and affective dimension of oral pain with swallowing ( P < 0.05). The severity of oral mucositis was significantly associated with the overall intensity of oral pain ( P < 0.05). Although mean scores for oral pain were low, 8 subjects had clinically unacceptable pain VAS scores (>3) while receiving opioids. Fourteen subjects had measurable increases in buccal TNF-α RNA expression at day 9 ( P = 0.027 vs baseline), as measured using the TRIzol method, which was found to be the best method for measuring this variable. TNF-α RNA content in buccal samples was significantly associated with the worst intensity of oral pain with swallowing (partial R 2 = 0.19; P < 0.05). Conclusions: Despite the use of opioids, oropharyngeal pain remained a treatment challenge in approximately one third of these subjects after CT with HSCT. The sensitive assay used to measure TNF-α gene expression in buccal cells may be useful in investigating molecular events in oral mucositis-related pain, as well as in evaluating the therapeutic response to investigational agents. Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-alpha (TNF-alpha) is a key pathogenic component of oral mucositis.BACKGROUNDOral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-alpha (TNF-alpha) is a key pathogenic component of oral mucositis.The primary purpose of this study was to describe oral mucositis-related oropharyngeal pain in the setting of HSCT. A secondary purpose was to assess the effectiveness of molecular biology methods for measuring TNF-alpha concentrations in plasma, saliva, and buccal epithelial cells in patients with oral mucositis undergoing HSCT.OBJECTIVESThe primary purpose of this study was to describe oral mucositis-related oropharyngeal pain in the setting of HSCT. A secondary purpose was to assess the effectiveness of molecular biology methods for measuring TNF-alpha concentrations in plasma, saliva, and buccal epithelial cells in patients with oral mucositis undergoing HSCT.This descriptive, correlative study recruited subjects aged >or= 18 years who were scheduled to receive HSCT with CT. Subjects assessed their pain at baseline and 9 days (+/-24 hours) after CT using a pain visual analog scale (VAS) from 0=no pain to 10=worst possible pain, as well as word descriptors of sensory and affective pain. The extent and severity of oral mucositis were evaluated using the Oral Mucositis Assessment Scale. Saliva and blood samples and buccal brush biopsies were obtained at the same time points. Salivary and plasma TNF-alpha concentrations were measured using an enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction testing was used to measure buccal TNF-alpha gene expression. To determine the optimal method of RNA isolation, samples were extracted using 3 different methods: TRIzol, RNeasy, and RLT/TRIzol.METHODSThis descriptive, correlative study recruited subjects aged >or= 18 years who were scheduled to receive HSCT with CT. Subjects assessed their pain at baseline and 9 days (+/-24 hours) after CT using a pain visual analog scale (VAS) from 0=no pain to 10=worst possible pain, as well as word descriptors of sensory and affective pain. The extent and severity of oral mucositis were evaluated using the Oral Mucositis Assessment Scale. Saliva and blood samples and buccal brush biopsies were obtained at the same time points. Salivary and plasma TNF-alpha concentrations were measured using an enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction testing was used to measure buccal TNF-alpha gene expression. To determine the optimal method of RNA isolation, samples were extracted using 3 different methods: TRIzol, RNeasy, and RLT/TRIzol.Twenty-five adult men and women (mean age, 46 years; age range, 32-68 years; 64% white) underwent HSCT with CT. Significant differences from baseline to day 9 were observed in the severity of oral mucositis (P<0.001), the overall intensity of oral pain (P<0.05), the overall intensity of oral pain with swallowing (P<0.01), the sensory dimension of oral pain with swallowing (P<0.05), and the sensory and affective dimension of oral pain with swallowing (P<0.05). The severity of oral mucositis was significantly associated with the overall intensity of oral pain (P<0.05). Although mean scores for oral pain were low, 8 subjects had clinically unacceptable pain VAS scores (>3) while receiving opioids. Fourteen subjects had measurable increases in buccal TNF-alpha RNA expression at day 9 (P=0.027 vs baseline), as measured using the TRIzol method, which was found to be the best method for measuring this variable. TNF-alpha RNA content in buccal samples was significantly associated with the worst intensity of oral pain with swallowing (partial R(2)=0.19; P<0.05).RESULTSTwenty-five adult men and women (mean age, 46 years; age range, 32-68 years; 64% white) underwent HSCT with CT. Significant differences from baseline to day 9 were observed in the severity of oral mucositis (P<0.001), the overall intensity of oral pain (P<0.05), the overall intensity of oral pain with swallowing (P<0.01), the sensory dimension of oral pain with swallowing (P<0.05), and the sensory and affective dimension of oral pain with swallowing (P<0.05). The severity of oral mucositis was significantly associated with the overall intensity of oral pain (P<0.05). Although mean scores for oral pain were low, 8 subjects had clinically unacceptable pain VAS scores (>3) while receiving opioids. Fourteen subjects had measurable increases in buccal TNF-alpha RNA expression at day 9 (P=0.027 vs baseline), as measured using the TRIzol method, which was found to be the best method for measuring this variable. TNF-alpha RNA content in buccal samples was significantly associated with the worst intensity of oral pain with swallowing (partial R(2)=0.19; P<0.05).Despite the use of opioids, oropharyngeal pain remained a treatment challenge in approximately one third of these subjects after CT with HSCT. The sensitive assay used to measure TNF-alpha gene expression in buccal cells may be useful in investigating molecular events in oral mucositis-related pain, as well as in evaluating the therapeutic response to investigational agents.CONCLUSIONSDespite the use of opioids, oropharyngeal pain remained a treatment challenge in approximately one third of these subjects after CT with HSCT. The sensitive assay used to measure TNF-alpha gene expression in buccal cells may be useful in investigating molecular events in oral mucositis-related pain, as well as in evaluating the therapeutic response to investigational agents. Abstract Background: Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of most of the associated pain. Tumor necrosis factor-α (TNF-α) is a key pathogenic component of oral mucositis. Objectives: The primary purpose of this study was to describe oral mucositis-related oropharyngeal pain in the setting of HSCT. A secondary purpose was to assess the effectiveness of molecular biology methods for measuring TNF-α concentrations in plasma, saliva, and buccal epithelial cells in patients with oral mucositis undergoing HSCT. Methods: This descriptive, correlative study recruited subjects aged ≥ 18 years who were scheduled to receive HSCT with CT. Subjects assessed their pain at baseline and 9 days (±24 hours) after CT using a pain visual analog scale (VAS) from 0 = no pain to 10 = worst possible pain, as well as word descriptors of sensory and affective pain. The extent and severity of oral mucositis were evaluated using the Oral Mucositis Assessment Scale. Saliva and blood samples and buccal brush biopsies were obtained at the same time points. Salivary and plasma TNF-**α concentrations were measured using an enzyme-linked immunosorbent assay. Quantitative real-time polymerase chain reaction testing was used to measure buccal TNF-α gene expression. To determine the optimal method of RNA isolation, samples were extracted using 3 different methods: TRIzol, RNeasy, and RLT/TRIzol. Results: Twenty-five adult men and women (mean age, 46 years; age range, 32-68 years; 64% white) underwent HSCT with CT. Significant differences from baseline to day 9 were observed in the severity of oral mucositis ( P < 0.001), the overall intensity of oral pain ( P < 0.05), the overall intensity of oral pain with swallowing ( P < 0.01), the sensory dimension of oral pain with swallowing ( P < 0.05), and the sensory and affective dimension of oral pain with swallowing ( P < 0.05). The severity of oral mucositis was significantly associated with the overall intensity of oral pain ( P < 0.05). Although mean scores for oral pain were low, 8 subjects had clinically unacceptable pain VAS scores (>3) while receiving opioids. Fourteen subjects had measurable increases in buccal TNF-α RNA expression at day 9 ( P = 0.027 vs baseline), as measured using the TRIzol method, which was found to be the best method for measuring this variable. TNF-α RNA content in buccal samples was significantly associated with the worst intensity of oral pain with swallowing (partial R2 = 0.19; P < 0.05). Conclusions: Despite the use of opioids, oropharyngeal pain remained a treatment challenge in approximately one third of these subjects after CT with HSCT. The sensitive assay used to measure TNF-α gene expression in buccal cells may be useful in investigating molecular events in oral mucositis-related pain, as well as in evaluating the therapeutic response to investigational agents. |
| Author | Castro, Kathleen Ramsay, Edward S. Sportés, Claude FalI-Dickson, Jane M. Woltz, Patricia |
| Author_xml | – sequence: 1 givenname: Jane M. surname: FalI-Dickson fullname: FalI-Dickson, Jane M. email: dicksonj@mail.nih.gov organization: Mucosal Injury Unit, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland – sequence: 2 givenname: Edward S. surname: Ramsay fullname: Ramsay, Edward S. organization: Laboratory of Symptom Management, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland – sequence: 3 givenname: Kathleen surname: Castro fullname: Castro, Kathleen organization: Clinical Center, Nursing and Patient Care Services, Research and Practice Development Service, National Institutes of Health, Bethesda, Maryland – sequence: 4 givenname: Patricia surname: Woltz fullname: Woltz, Patricia organization: Mucosal Injury Unit, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland – sequence: 5 givenname: Claude surname: Sportés fullname: Sportés, Claude organization: Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18164921$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks1uEzEUhS1URNPCK4BX7CbYE8_fAlAUtRSpEERTiZ3lse-kDh57ansq-kyseBGeCY9SuqiE6MoLn-_4-px7hA6ss4DQK0rmlNDyzW4ujbbxCryY54RUc5rPCWFP0IzWVZNRyr4doBmhrMnyhtaH6CiEHSFk0RT5M3RIa1qyJqcz9HPthcGfRumCjjpkX8GICAqvvRuuhL-1W0j3X4S2WFiFV877SaFvAG_G3nn8GaRPbMCnQkbns9-_8MmPwUMI2lmcsKUaTcRrK51x29tkFTXYGPClVeC3TtstPoNeRDc4DVFLfBGhxyswBm-8sGEwwsYEOfscPe2ECfDi7jxGl6cnm9VZdr7-8HG1PM8kq0nMqqLsOkZbKTslZFstChB5iqLshGqkqJho25xRWksiZK2gLQrGFq0oSqHapmkXx-j13nfw7nqEEHmvg0wDCQtuDLxsSN0sGEnCl3fCse1B8cHrPmXG_8abBG_3gimj4KHjUu__Er3QhlPCpzr5jt_Xyac6Oc15qjPx1QP-_on_kss9CSmoGw2eB5lyl6C0Bxm5cvoRHu8eeEw6LYX5DrcQdm70NvXAKQ8J4BfTuk3bRqq0aFU-Gbz_t8GjRvgDZ2_wLA |
| CitedBy_id | crossref_primary_10_1002_ijc_25200 crossref_primary_10_1016_j_radonc_2009_12_005 crossref_primary_10_1111_odi_14857 crossref_primary_10_1016_j_ejpb_2018_04_025 crossref_primary_10_1093_jncimonographs_lgz003 crossref_primary_10_1186_2008_2231_22_51 crossref_primary_10_1007_s00520_011_1277_7 crossref_primary_10_1007_s00277_024_06122_y crossref_primary_10_1371_journal_pone_0169286 crossref_primary_10_1007_s00520_009_0708_1 crossref_primary_10_1177_0022034514540174 crossref_primary_10_1002_lsm_22349 crossref_primary_10_3390_jcm13102822 crossref_primary_10_1016_j_soncn_2021_151160 crossref_primary_10_1016_j_oooo_2011_10_012 crossref_primary_10_1007_s00520_009_0618_2 crossref_primary_10_1007_s00520_023_07947_5 crossref_primary_10_1016_j_oooo_2017_08_002 crossref_primary_10_1016_j_soncn_2011_08_001 crossref_primary_10_1038_s41598_022_20475_2 crossref_primary_10_1016_j_bbmt_2019_01_026 crossref_primary_10_1007_s00520_009_0771_7 crossref_primary_10_1016_j_cyto_2021_155506 crossref_primary_10_1007_s00520_010_0940_8 crossref_primary_10_1038_s41598_025_87608_1 |
| Cites_doi | 10.1016/0003-2697(87)90021-2 10.1111/j.1601-0825.2006.01258.x 10.1002/cncr.20163 10.1081/CNV-120002497 10.1016/S1085-5629(97)80015-6 10.1046/j.1523-5394.1999.75008.x 10.1016/0885-3924(96)00128-5 10.1200/JCO.2001.19.8.2201 10.1038/sj.bmt.1702447 10.1002/cncr.20162 10.1002/14651858.CD003139 10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0 10.1038/nrc1318 10.1016/0304-3959(94)00153-6 10.1016/j.ctrv.2007.03.001 10.1016/S1462-3889(07)70004-2 10.1177/154405910608500802 |
| ContentType | Journal Article |
| Copyright | 2007 Excerpta Medica, Inc. Excerpta Medica, Inc. |
| Copyright_xml | – notice: 2007 Excerpta Medica, Inc. – notice: Excerpta Medica, Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.clinthera.2007.12.004 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 2561 |
| ExternalDocumentID | 18164921 10_1016_j_clinthera_2007_12_004 S0149291807003724 1_s2_0_S0149291807003724 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- ~HD 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU LCYCR 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM 7X8 PUEGO |
| ID | FETCH-LOGICAL-c480t-756ff41bccfdacb735ea20146fad9ca74abb24118c0ac8deb55443ba56adb99b3 |
| ISICitedReferencesCount | 27 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000252211600006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0149-2918 |
| IngestDate | Thu Oct 02 09:48:39 EDT 2025 Wed Feb 19 01:48:29 EST 2025 Tue Nov 18 21:09:39 EST 2025 Sat Nov 29 03:56:30 EST 2025 Fri Feb 23 02:23:24 EST 2024 Sun Feb 23 10:18:56 EST 2025 Tue Oct 14 19:28:44 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c480t-756ff41bccfdacb735ea20146fad9ca74abb24118c0ac8deb55443ba56adb99b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 18164921 |
| PQID | 69089340 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | proquest_miscellaneous_69089340 pubmed_primary_18164921 crossref_citationtrail_10_1016_j_clinthera_2007_12_004 crossref_primary_10_1016_j_clinthera_2007_12_004 elsevier_sciencedirect_doi_10_1016_j_clinthera_2007_12_004 elsevier_clinicalkeyesjournals_1_s2_0_S0149291807003724 elsevier_clinicalkey_doi_10_1016_j_clinthera_2007_12_004 |
| PublicationCentury | 2000 |
| PublicationDate | 2007 2007-1-00 2007-00-00 20070101 |
| PublicationDateYYYYMMDD | 2007-01-01 |
| PublicationDate_xml | – year: 2007 text: 2007 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2007 |
| Publisher | EM Inc USA |
| Publisher_xml | – name: EM Inc USA |
| References | Gaston-Johansson, Franco, Zimmerman (bib3) 1992; 19 Gaston-Johansson, Ohly, Fall-Dickson (bib26) 1999; 26 Sonis (bib12) 2004; 4 Jacox, Carr, Payne (bib18) 1994 Syrjala, Chapko (bib8) 1995; 61 Gaston-Johansson, FalI-Dickson, Bakos, Kennedy (bib11) 1999; 7 FalI-Dickson (bib20) 2002 Chomczynski, Sacchi (bib24) 1987; 162 Stokman, Spijkervet, Boezen (bib25) 2006; 85 (bib19) 1994 Fliedner, Baguet, Blankart (bib6) 2007; 11 Eisen, Essell, Broun (bib9) 1997; 16 Gaston-Johansson (bib21) 1996; 12 Logan, Stringer, Bowen (bib27) 2007; 33 Rubenstein, Peterson, Schubert (bib17) 2004; 100 (bib23) 2001 Scully, Sonis, Diz (bib7) 2006; 12 Sonis, Elting, Keefe (bib14) 2004; 100 Hargreaves, Milam (bib16) 2002 Gaston-Johansson, FalI-Dickson, Nanda (bib2) 2000; 23 Sonis, Eilers, Epstein (bib22) 1999; 85 Aggarwal, Samanta, Feldmann (bib15) 2001 Sonis, Oster, Fuchs (bib10) 2001; 19 Farquhar, Basser, Hetrick (bib1) 2003; 1 Blijlevens, Donnelly, De Pauw (bib13) 2000; 25 Hyland (bib4) 1997 Bellm, Cunningham, Durnell (bib5) 2002; 20 Fliedner (10.1016/j.clinthera.2007.12.004_bib6) 2007; 11 Sonis (10.1016/j.clinthera.2007.12.004_bib12) 2004; 4 Gaston-Johansson (10.1016/j.clinthera.2007.12.004_bib21) 1996; 12 Bellm (10.1016/j.clinthera.2007.12.004_bib5) 2002; 20 Gaston-Johansson (10.1016/j.clinthera.2007.12.004_bib2) 2000; 23 Logan (10.1016/j.clinthera.2007.12.004_bib27) 2007; 33 (10.1016/j.clinthera.2007.12.004_bib19) 1994 Stokman (10.1016/j.clinthera.2007.12.004_bib25) 2006; 85 Aggarwal (10.1016/j.clinthera.2007.12.004_bib15) 2001 Blijlevens (10.1016/j.clinthera.2007.12.004_bib13) 2000; 25 Chomczynski (10.1016/j.clinthera.2007.12.004_bib24) 1987; 162 (10.1016/j.clinthera.2007.12.004_bib23) 2001 Gaston-Johansson (10.1016/j.clinthera.2007.12.004_bib26) 1999; 26 Gaston-Johansson (10.1016/j.clinthera.2007.12.004_bib11) 1999; 7 Rubenstein (10.1016/j.clinthera.2007.12.004_bib17) 2004; 100 Syrjala (10.1016/j.clinthera.2007.12.004_bib8) 1995; 61 Hargreaves (10.1016/j.clinthera.2007.12.004_bib16) 2002 FalI-Dickson (10.1016/j.clinthera.2007.12.004_bib20) 2002 Sonis (10.1016/j.clinthera.2007.12.004_bib10) 2001; 19 Sonis (10.1016/j.clinthera.2007.12.004_bib22) 1999; 85 Scully (10.1016/j.clinthera.2007.12.004_bib7) 2006; 12 Sonis (10.1016/j.clinthera.2007.12.004_bib14) 2004; 100 Gaston-Johansson (10.1016/j.clinthera.2007.12.004_bib3) 1992; 19 Jacox (10.1016/j.clinthera.2007.12.004_bib18) 1994 Farquhar (10.1016/j.clinthera.2007.12.004_bib1) 2003; 1 Hyland (10.1016/j.clinthera.2007.12.004_bib4) 1997 Eisen (10.1016/j.clinthera.2007.12.004_bib9) 1997; 16 |
| References_xml | – start-page: 14 year: 2002 end-page: 33 ident: bib16 article-title: Mechanisms of orofacial pain and analgesia publication-title: Management of Pain and Anxiety in the Dental Office – volume: 25 start-page: 1269 year: 2000 end-page: 1278 ident: bib13 article-title: Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment For haematological malignancy: An overview publication-title: Bone Marrow Transplant – volume: 16 start-page: 265 year: 1997 end-page: 272 ident: bib9 article-title: Oral cavity complications of bone marrow transplantation publication-title: Semin Cutan Med Surg – volume: 162 start-page: 156 year: 1987 end-page: 159 ident: bib24 article-title: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction publication-title: Anal Biochem – volume: 19 start-page: 2201 year: 2001 end-page: 2205 ident: bib10 article-title: Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation publication-title: J Clin Oncol – start-page: 37 year: 1994 end-page: 38 ident: bib18 article-title: Mucositis publication-title: Management of Cancer Pain: Clinical Practice Guideline No. 9. Rockville, Md: Agency for Health Care Policy and Research, US Dept of Health and Human Services, Public Health Service – volume: 4 start-page: 277 year: 2004 end-page: 284 ident: bib12 article-title: The pathobiology of mucositis publication-title: Nat Rev Cancer – volume: 85 start-page: 2103 year: 1999 end-page: 2113 ident: bib22 article-title: Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy publication-title: Cancer – start-page: 413 year: 2001 end-page: 434 ident: bib15 article-title: TNFα publication-title: Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense – start-page: 385 year: 2002 end-page: 400 ident: bib20 article-title: Treatment of stomatitis and associated oropharyngeal pain in the oncology patient publication-title: Management of Pain and Anxiety in the Dental Office – volume: 11 start-page: S19 year: 2007 end-page: S26 ident: bib6 article-title: Palifermin for patients with haematological malignancies: Shifting nursing practice from symptom relief to prevention of oral mucositis publication-title: Eur J Oncol Nurs – volume: 23 start-page: 277 year: 2000 end-page: 285 ident: bib2 article-title: The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation publication-title: Cancer Nuts – year: 2001 ident: bib23 publication-title: RNeasy Mini Handbook – volume: 20 start-page: 793 year: 2002 end-page: 800 ident: bib5 article-title: Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board publication-title: Cancer Invest – volume: 7 start-page: 240 year: 1999 end-page: 247 ident: bib11 article-title: Fatigue, pain, and depression in pre-auto-transplant breast cancer patients publication-title: Cancer Pract. – volume: 85 start-page: 690 year: 2006 end-page: 700 ident: bib25 article-title: Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of meta-analyses publication-title: J Dent Res – volume: 1 year: 2003 ident: bib1 article-title: High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer publication-title: Cochrane Database Syst Rev. – volume: 12 start-page: 229 year: 2006 end-page: 241 ident: bib7 article-title: Oral mucositis publication-title: Oral Dis – volume: 12 start-page: 172 year: 1996 end-page: 181 ident: bib21 article-title: Measurement of pain: The psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices publication-title: J Pain Symptom Manage – volume: 100 start-page: 1995 year: 2004 end-page: 2025 ident: bib14 article-title: Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients publication-title: Cancer – start-page: 23 year: 1994 end-page: 42 ident: bib19 article-title: National Institute of Nursing Research publication-title: The Nature of Pain: A Conceptual Perspective. A Report of the NINR Priority Expert Panel on Symptom Management: Acute Pain – start-page: 519 year: 1997 end-page: 527 ident: bib4 article-title: Assessing the oral cavity publication-title: Instruments for Clinical Health-Care Research – volume: 61 start-page: 69 year: 1995 end-page: 79 ident: bib8 article-title: Evidence for a biopsychosocial model of cancer treatment-related pain publication-title: Pain – volume: 33 start-page: 448 year: 2007 end-page: 460 ident: bib27 article-title: The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs publication-title: Cancer Treat Rev – volume: 26 start-page: 1337 year: 1999 end-page: 1345 ident: bib26 article-title: Pain, psychological distress, health status, and coping in patients with breast cancer scheduled for autotransplantation publication-title: Oncol Nurs Forum – volume: 19 start-page: 41 year: 1992 end-page: 48 ident: bib3 article-title: Pain and psychological distress in patients undergoing autologous bone marrow transplantation publication-title: Oncol Nurs Forum – volume: 100 start-page: 2026 year: 2004 end-page: 2046 ident: bib17 article-title: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis publication-title: Cancer – volume: 162 start-page: 156 year: 1987 ident: 10.1016/j.clinthera.2007.12.004_bib24 article-title: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction publication-title: Anal Biochem doi: 10.1016/0003-2697(87)90021-2 – start-page: 413 year: 2001 ident: 10.1016/j.clinthera.2007.12.004_bib15 article-title: TNFα – volume: 12 start-page: 229 year: 2006 ident: 10.1016/j.clinthera.2007.12.004_bib7 article-title: Oral mucositis publication-title: Oral Dis doi: 10.1111/j.1601-0825.2006.01258.x – start-page: 519 year: 1997 ident: 10.1016/j.clinthera.2007.12.004_bib4 article-title: Assessing the oral cavity – start-page: 37 year: 1994 ident: 10.1016/j.clinthera.2007.12.004_bib18 article-title: Mucositis publication-title: Management of Cancer Pain: Clinical Practice Guideline No. 9. Rockville, Md: Agency for Health Care Policy and Research, US Dept of Health and Human Services, Public Health Service – volume: 100 start-page: 2026 issue: SuppI 9 year: 2004 ident: 10.1016/j.clinthera.2007.12.004_bib17 article-title: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis publication-title: Cancer doi: 10.1002/cncr.20163 – volume: 20 start-page: 793 year: 2002 ident: 10.1016/j.clinthera.2007.12.004_bib5 article-title: Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board publication-title: Cancer Invest doi: 10.1081/CNV-120002497 – volume: 16 start-page: 265 year: 1997 ident: 10.1016/j.clinthera.2007.12.004_bib9 article-title: Oral cavity complications of bone marrow transplantation publication-title: Semin Cutan Med Surg doi: 10.1016/S1085-5629(97)80015-6 – volume: 7 start-page: 240 year: 1999 ident: 10.1016/j.clinthera.2007.12.004_bib11 article-title: Fatigue, pain, and depression in pre-auto-transplant breast cancer patients publication-title: Cancer Pract. doi: 10.1046/j.1523-5394.1999.75008.x – volume: 12 start-page: 172 year: 1996 ident: 10.1016/j.clinthera.2007.12.004_bib21 article-title: Measurement of pain: The psychometric properties of the Pain-O-Meter, a simple, inexpensive pain assessment tool that could change health care practices publication-title: J Pain Symptom Manage doi: 10.1016/0885-3924(96)00128-5 – year: 2001 ident: 10.1016/j.clinthera.2007.12.004_bib23 – start-page: 23 year: 1994 ident: 10.1016/j.clinthera.2007.12.004_bib19 article-title: National Institute of Nursing Research – volume: 19 start-page: 2201 year: 2001 ident: 10.1016/j.clinthera.2007.12.004_bib10 article-title: Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.8.2201 – volume: 25 start-page: 1269 year: 2000 ident: 10.1016/j.clinthera.2007.12.004_bib13 article-title: Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment For haematological malignancy: An overview publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1702447 – volume: 100 start-page: 1995 issue: SuppI 9 year: 2004 ident: 10.1016/j.clinthera.2007.12.004_bib14 article-title: Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients publication-title: Cancer doi: 10.1002/cncr.20162 – volume: 26 start-page: 1337 year: 1999 ident: 10.1016/j.clinthera.2007.12.004_bib26 article-title: Pain, psychological distress, health status, and coping in patients with breast cancer scheduled for autotransplantation publication-title: Oncol Nurs Forum – volume: 1 year: 2003 ident: 10.1016/j.clinthera.2007.12.004_bib1 article-title: High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer publication-title: Cochrane Database Syst Rev. doi: 10.1002/14651858.CD003139 – volume: 85 start-page: 2103 year: 1999 ident: 10.1016/j.clinthera.2007.12.004_bib22 article-title: Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0 – volume: 23 start-page: 277 year: 2000 ident: 10.1016/j.clinthera.2007.12.004_bib2 article-title: The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation publication-title: Cancer Nuts – volume: 4 start-page: 277 year: 2004 ident: 10.1016/j.clinthera.2007.12.004_bib12 article-title: The pathobiology of mucositis publication-title: Nat Rev Cancer doi: 10.1038/nrc1318 – volume: 61 start-page: 69 year: 1995 ident: 10.1016/j.clinthera.2007.12.004_bib8 article-title: Evidence for a biopsychosocial model of cancer treatment-related pain publication-title: Pain doi: 10.1016/0304-3959(94)00153-6 – volume: 33 start-page: 448 year: 2007 ident: 10.1016/j.clinthera.2007.12.004_bib27 article-title: The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2007.03.001 – volume: 19 start-page: 41 year: 1992 ident: 10.1016/j.clinthera.2007.12.004_bib3 article-title: Pain and psychological distress in patients undergoing autologous bone marrow transplantation publication-title: Oncol Nurs Forum – volume: 11 start-page: S19 issue: Suppl1 year: 2007 ident: 10.1016/j.clinthera.2007.12.004_bib6 article-title: Palifermin for patients with haematological malignancies: Shifting nursing practice from symptom relief to prevention of oral mucositis publication-title: Eur J Oncol Nurs doi: 10.1016/S1462-3889(07)70004-2 – volume: 85 start-page: 690 year: 2006 ident: 10.1016/j.clinthera.2007.12.004_bib25 article-title: Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of meta-analyses publication-title: J Dent Res doi: 10.1177/154405910608500802 – start-page: 14 year: 2002 ident: 10.1016/j.clinthera.2007.12.004_bib16 article-title: Mechanisms of orofacial pain and analgesia – start-page: 385 year: 2002 ident: 10.1016/j.clinthera.2007.12.004_bib20 article-title: Treatment of stomatitis and associated oropharyngeal pain in the oncology patient |
| SSID | ssj0003952 |
| Score | 1.9925616 |
| Snippet | Background: Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal... Abstract Background: Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the... Oral mucositis is the most common sequela of conditioning chemotherapy (CT) for hematopoietic stem cell transplantation (HSCT) and is the principal cause of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2547 |
| SubjectTerms | Adult Aged Female Hematopoietic Stem Cell Transplantation - adverse effects Humans Internal Medicine Male Medical Education Middle Aged Neoplasms - therapy Pain - etiology Reverse Transcriptase Polymerase Chain Reaction Saliva - chemistry Stomatitis - etiology Stomatitis - physiopathology Tumor Necrosis Factor-alpha - analysis Tumor Necrosis Factor-alpha - blood Tumor Necrosis Factor-alpha - genetics |
| Title | Oral Mucositis-Related Oropharyngeal Pain and Correlative Tumor Necrosis Factor-α Expression in Adult Oncology Patients Undergoing Hematopoietic Stem Cell Transplantation |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291807003724 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291807003724 https://dx.doi.org/10.1016/j.clinthera.2007.12.004 https://www.ncbi.nlm.nih.gov/pubmed/18164921 https://www.proquest.com/docview/69089340 |
| Volume | 29 |
| WOSCitedRecordID | wos000252211600006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-114X dateEnd: 20130831 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1879-114X dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database (ProQuest) customDbUrl: eissn: 1879-114X dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1879-114X dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1879-114X dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1879-114X dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9tAEF6lUFW9VC19pQ-6h8IlGPm9dm-QgmilPAShys1ar20alNhRHBD8pp76R_p7euzMrh8JD0FV9bJKnGzsZL7Mzo6_-YaQj67DBU8sXzPjRNfsxHU0WBS4hreoPMcNTT1OZLMJ1u16w6HfbzR-l7Uw52OWpt7FhT_9r6aGY2BsLJ39C3NXHwoH4DEYHUYwO4z3MnwPS-47SERHuSJNst0gquzNsul3PrtMT1BKuM9HioXcxu4cY6X-PTibZFgCjCvnKG_ty1Y82kZ7b2PXQE1kRZmV1MgdlO1o9VKhJJz6Sp0VyTZRPDvJMP9wgGqw2TQbYZkksskmrTYmCpWc-pinCySAUiqhLNNcqAqr61P4-Iv2eVRJAnzlEB93tusbVZOcS8SoPtSto-qlNs_nqpyn5I5US1E2nqsMuuxUMOJLSRBW5-Q66Ehbx0c7S0lSwJ5f-PVYOXaP-Rrs_YaLnr_ItRQINxb9uKN0QIuYAOJC48b1RqU-TrexjFX-NEoUExPMqqvyFTFv5NL5eGngaXWLmfYDsmoyx0cyIjv8VsUQli97RVXfZImZeOPJbourbts3yfhp8JQ8KTY-dEcB9hlpxOkaedQpqB1rZLOvRNQvt-hgwfpbdJP2a3n1y-fkBwKcXgM4XQI4RYBTADhdADiVAKclwGkB8F8_aQ1uCtMkuGkJblqCm9bgpkvgpghuiuCmV8D9ghzv7w3aB1rRckQTtqfPNea4SWIboRBJxEXILCfmJuorJTzyBWc2D0OIeQ1P6Fx4URw6qB8ZcsflUej7ofWSrKRZGr8mNDSFKxzcHvgQNUcGt6IkNnVmusISjms1iVsaLBCFHj-2hRkHJfHyNKgsjd1iWWCYAVi6SfRq4lRJ0tw9xSsREZQV1xAjBADju6eym6bGeeHy8sAIcnhncA3aTfKpmlmE8ypMv99pP5TADWDBw7uY4FWyszxwkalg2XqTvFJ4rn8EWGDgEow3_3Lit-Sxun2DWdZ3ZGU-O4vfk4fiHBA9W5f_UhyHTI7eOlnd3ev2D-FZRx_gaPb-AA1ZQTg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+Mucositis-Related+Oropharyngeal+Pain+and+Correlative+Tumor+Necrosis+Factor-%CE%B1+Expression+in+Adult+Oncology+Patients+Undergoing+Hematopoietic+Stem+Cell+Transplantation&rft.jtitle=Clinical+therapeutics&rft.au=FalI-Dickson%2C+Jane+M.&rft.au=Ramsay%2C+Edward+S.&rft.au=Castro%2C+Kathleen&rft.au=Woltz%2C+Patricia&rft.date=2007&rft.pub=EM+Inc+USA&rft.issn=0149-2918&rft.eissn=1879-114X&rft.volume=29&rft.issue=11&rft.spage=2547&rft.epage=2561&rft_id=info:doi/10.1016%2Fj.clinthera.2007.12.004&rft.externalDocID=S0149291807003724 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291807X81220%2Fcov150h.gif |